- Home
- SABS vs MUZE Comparison
SABS vs MUZE Comparison
Compare SABS & MUZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SABS | MUZE |
|---|---|---|
| Founded | 2014 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.9M | 271.6M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SABS | MUZE |
|---|---|---|
| Price | $3.01 | $10.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $11.64 | N/A |
| AVG Volume (30 Days) | ★ 672.8K | 25.4K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.53 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $9.83 |
| 52 Week High | $5.15 | $10.04 |
Technical Indicators
Market Signals| Indicator | SABS | MUZE |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 67.14 |
| Support Level | $2.44 | $9.99 |
| Resistance Level | $4.03 | N/A |
| Average True Range (ATR) | 0.23 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 38.33 | 100.00 |
Price Performance
Historical ComparisonAbout SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.